2013年10月10日讯 /生物谷BIOON/ --强生（JNJ）旗下杨森（Janssen）10月8日宣布，已从葛兰素史克（GSK）旗下子公司收购了实验性 ...

2017年6月9日/生物谷BIOON/---据估计，在全球有7100万人感染上慢性丙型肝炎病毒（HCV）。在几十年的感染后，慢性HCV感染导致 ...

为解决非洲非 1a/1b HCV 1 亚型难诊疗问题，研究发现 NS5A 区域可辅助检测及治疗选择。 在撒哈拉以南非洲地区，非 1a/1b 型丙型肝炎病毒（HCV）1 亚型较为常见。这些变异体在 NS5A 区域存在与耐药相关的自然多态性替代，难以对其进行特征描述和治疗。研究人员 ...

Figure 1. The direct-acting antiviral targets in the hepatitis C virus replication cycle. NS3/4A protease inhibitors target the NS3/4A protease enzyme which is needed for the virus to develop the ...

Background. Hepatitis C virus (HCV) genotype 1 is the most prevalent genotype in Western countries, and treatment with pegylated interferon (pegIFN) plus ribavirin fails in 50%-60% of patients.

DUBLIN, IRELAND and CAMBRIDGE, MA--(Marketwired - Oct 27, 2015) - Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Trek Therapeutics ("TREKtx") today announced that TREKtx has ...

TITUSVILLE, N.J., Oct. 8, 2013 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (Janssen) announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio VIENNA — NS5A resistance-associated ...

What to Do With a Positive Hepatitis C Test Findings from a study published in Hepatology support retreating patients with NS5A inhibitor failures with sofosbuvir + simeprevir. Findings from a study ...